Jumpcan Pharmaceutical has entered into an exclusive commercialisation agreement with Chinese compatriot Thederma for the rights to benvitimod cream in Mainland China. Under the agreement, Jumpcan will pay up to RMB 190 million (including tax) in an upfront and milestone payments. The deal grants Jumpcan exclusive rights to commercialise the topical therapy for atopic dermatitis (eczema) in patients aged 2 and above.

Benvitimod cream, a first-in-class AhR modulator, was approved in China in November 2024. It is positioned as a non-steroidal treatment option, particularly for paediatric patients and for use on sensitive skin areas. The product is in the early stages of market penetration and is not yet included in China's National Reimbursement Drug List (NRDL). The domestic atopic dermatitis drug market, estimated at RMB 11 billion in 2024, is projected to grow significantly, providing a substantial commercial opportunity for the therapy.

PharmCube's NextBiopharm® database lists a total of 19 AhR agonists under development globally, led by benvitimod. Click here to request a free trial for NextBiopharm®.